Oasmia Pharmaceutical AB

    [td_text_with_title custom_title=”Company description”]
    Improved quality of life for humans and animals

    Oasmia Pharmaceutical AB develops a new generation of drugs within human and veterinary oncology. The product development aims to manufacture novel formulations based on well-established cytostatics which, in comparison with current alternatives, show improved properties, a reduced side-effect profile and an expanded therapeutic area. The product development is based on in-house research within nanotechnology and company patents.

    [/td_text_with_title]
    [td_text_with_title custom_title=”Latest post”]
    oasmia-logo

    Oasmia Pharmaceutical – betting on a unfulfilled promise

    In 2010 Oasmia Pharmaceutical was listed on the Nasdaq OMX with Carnegie as primary advisor. They wrote an analysis prior to the listing which is a good read when you as a sceptic investor want to view other analysis in the sector. As a whole I found the timelines in drug development far to optimistic […]

    0 comments
    oasmia-logo

    Oasmia files for US IPO

    Ladenburg Thalmann is acting as lead book-running manager for the proposed offering, which is expected to close on July 30, 2015 at the latest, subject to customary closing conditions. “This is a very exciting time for Oasmia, as we progress through the final stages of the filing and NASDAQ listing process to create exposure to […]

    0 comments
    [/td_text_with_title]